FGR
ENSG00000000938
Target class
Kinase
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
5
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- FGR
- Gene name
- FGR proto-oncogene, Src family tyrosine kinase
- Gene symbol
- FGR
- Previous gene symbols
- SRC2
- Protein name
- Tyrosine-protein kinase Fgr (EC 2.7.10.2) (Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog) (Proto-oncogene c-Fgr) (p55-Fgr) (p58-Fgr) (p58c-Fgr)
- c-fgr
- p55c-fgr
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 545.93
- Tissue specificity (Gini)
- 0.756
- Tissue specificity (tau)
- 0.972
- KEGG gene identifiers
- hsa:2268
- Protein interaction confidence
- 0.832303
- Protein interaction partners
- 33
- R-HSA-2029481
- R-HSA-432142
- R-HSA-6798695
- R-HSA-9664323
- R-HSA-9664422
- End position
- 27635565
- Start position
- 27612064
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Lipid-anchor
- Cytoplasmic side . Cell membrane
- Peripheral membrane protein
- Cytoplasmic side. Cell projection, ruffle membrane. Cytoplasm, cytosol. Cytoplasm, cytoskeleton. Mitochondrion inner membrane . Mitochondrion intermembrane space . Note=Detected in mitochondrial intermembrane space and at inner membranes (By similarity). Colocalizes with actin fibers at membrane ruffles. Detected at plasma membrane lipid rafts. .
- Aggresome
- Plasma membrane
- Tissue specificity (tau)
- 0.972032
- Expression inequality (Gini)
- 0.756041
Expression in transcripts per million
- Whole Blood
- 545.93
- Spleen
- 185.64
- Lung
- 135.38
- Cells - EBV-transformed lymphocytes
- 79.21
- Adipose - Subcutaneous
- 28.04
Expression in transcripts per million
- Whole Blood545.93
- Spleen185.64
- Lung135.38
- Cells - EBV-transformed lymphocytes79.21
- Adipose - Subcutaneous28.04
- Fallopian Tube27.9
- Adipose - Visceral (Omentum)26.86
- Breast - Mammary Tissue20.47
- Artery - Coronary16.75
- Uterus16.46
- Nerve - Tibial15.89
- Bladder13.99
- Cervix - Endocervix13.92
- Small Intestine - Terminal Ileum12.94
- Thyroid12.36
- Vagina11.26
- Cervix - Ectocervix10.52
- Prostate9.77
- Artery - Aorta8.76
- Esophagus - Gastroesophageal Junction8.23
- Brain - Spinal cord (cervical c-1)7.93
- Esophagus - Muscularis7.88
- Minor Salivary Gland7.63
- Adrenal Gland7.1
- Colon - Sigmoid6.88
And 29 more, listed on the interactive page.
- GO:0002768
- GO:0002862
- GO:0006468
- GO:0007229
- GO:0009615
- GO:0018108
- GO:0038096
- GO:0046777
- GO:0051897
- GO:0005576
- GO:0005829
- GO:0005856
- GO:0034774
- GO:0070062
- GO:0001784
- GO:0004713
- GO:0004715
- GO:0005515
- GO:0034988
Related records
Trials (705)
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioequivalence Study of Dasatinib Tablet
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Drugs (9)
- Apitolisib
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor